- Home
- TERN vs EIC Comparison
TERN vs EIC Comparison
Compare TERN & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- EIC
- Stock Information
- Founded
- TERN 2017
- EIC N/A
- Country
- TERN United States
- EIC United States
- Employees
- TERN N/A
- EIC N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- TERN Health Care
- EIC Finance
- Exchange
- TERN Nasdaq
- EIC Nasdaq
- Market Cap
- TERN 321.4M
- EIC 339.0M
- IPO Year
- TERN 2021
- EIC 2019
- Fundamental
- Price
- TERN $3.80
- EIC $13.64
- Analyst Decision
- TERN Buy
- EIC Strong Buy
- Analyst Count
- TERN 5
- EIC 1
- Target Price
- TERN $15.63
- EIC $17.50
- AVG Volume (30 Days)
- TERN 932.0K
- EIC 343.8K
- Earning Date
- TERN 08-04-2025
- EIC 08-05-2025
- Dividend Yield
- TERN N/A
- EIC 17.57%
- EPS Growth
- TERN N/A
- EIC N/A
- EPS
- TERN N/A
- EIC 0.55
- Revenue
- TERN N/A
- EIC $51,224,692.00
- Revenue This Year
- TERN N/A
- EIC $42.67
- Revenue Next Year
- TERN N/A
- EIC $29.16
- P/E Ratio
- TERN N/A
- EIC $24.76
- Revenue Growth
- TERN N/A
- EIC 68.61
- 52 Week Low
- TERN $1.87
- EIC $12.63
- 52 Week High
- TERN $11.40
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- TERN 61.74
- EIC 48.31
- Support Level
- TERN $3.66
- EIC $13.32
- Resistance Level
- TERN $4.30
- EIC $13.45
- Average True Range (ATR)
- TERN 0.31
- EIC 0.19
- MACD
- TERN -0.01
- EIC 0.07
- Stochastic Oscillator
- TERN 59.28
- EIC 93.33
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.